Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department

Haematologica

Volumn 98, Issue 11, 2013, Pages

  Díaz, Manuel Quintana ^a   Borobia, Alberto M ^a,b   Núñez, Ma Angelica Rivera ^a   Virto, Ana Maria Martínez ^a   Fabra, Sara ^a   Casado, Marcelino Sánchez ^c   García Erce, Jose A ^d   Samama, C Meyer ^e  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^c HOSPITAL VIRGEN DE LA SALUD   (Spain)

^d HOSPITAL SAN JORGE   (Spain)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bleeding; Dabigatran; Prothrombin complex concentrate; Reversal

Indexed keywords

DABIGATRAN; KANOKAD; PROTHROMBIN COMPLEX; UNCLASSIFIED DRUG;

AGED; BLOOD CLOTTING TEST; CLINICAL ARTICLE; DRUG EFFECT; DRUG REVERSAL EFFECT; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INTESTINAL BLEEDING; LETTER; MALE; PARTIAL THROMBOPLASTIN TIME; SCORING SYSTEM;

BLEEDING; DABIGATRAN; PROTHROMBIN COMPLEX CONCENTRATE; REVERSAL;

AGED; AGED, 80 AND OVER; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; EMERGENCY MEDICAL SERVICES; EMERGENCY SERVICE, HOSPITAL; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE;

EID: 84887005347     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.092767     Document Type: Letter

References (13)

1. European Medicines Agency [Internet]. Pradaxa dabigratan etexilate. London: The Association EMA Science Medicines Health [Update 2013 Jan 16; cited Jul 22]. Available from: http://www. ema. europa. eu/ema/index. jsp?curl=pages%2Fincludes %2Fmedicines%2Fmedicines_landing_page. jsp&searchkwByEnter =false&quickSearch=pradaxa&spanFlag=0&keywordSearch=Subm it.
2. Cao YB, Zhang JD, Shen H, Jiang YY. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2010; 66(11): 1099-108.
3. Pradaxa monograph. Boehringer-Ingelheim [Internet]. Ingelheim-Germany [update 2012 Dec 12; cited 2013 Feb 23]. Available from: ttp://www. boehringer-ingelheim. ca/en/Home/Human_Health/.
4. vanRyn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103(6): 1116-27.
5. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24): 2342-52.
6. Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart. 2012; 98(7): 573-8.
7. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med. 2012; 125(4): 417-20.
8. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5): 1093-100.
9. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost. 2012; 10(9): 1841-8.
10. Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield WP. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost. 2012; 10(9): 1830-40.
11. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects. Circulation. 2011; 124(14): 1573-9.
12. Clemenes A, van Ryn J, Sennewald R, Yamamura N, Stangier J, Feuring M, et al. Switching from enoxaparin to dabigatranetexilate: pharmacokinetics, pharmacodynamics, and safety profile. Eur J Clin Pharmacol. 2012; 68(5): 607-16.
13. Lillo-Le Louët A, Wolf M, Soufir L, Galbois A, Dumenil AS, Offenstadt G, et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitation. Thromb Haemost. 2012; 108(3): 583-5.